IRD — Opus Genetics Share Price
0.000.00%
Last trade - 00:00- $34.56m
- $23.08m
- $10.99m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.14 | ||
| Price to Tang. Book | 5.14 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.14 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -242.79% | ||
| Return on Equity | -203.19% | ||
| Operating Margin | -564.72% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.59 | 39.85 | 19.05 | 10.99 | 13.28 | 26.67 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Directors
- Cam Gallagher NEC (51)
- Mina Sooch PRE (53)
- Amy Rabourn CAO (41)
- Bernhard Hoffmann VOP (65)
- Sean Ainsworth LED (53)
- Jay Pepose DRC
- Susan Benton IND (56)
- James Manuso IND (72)
- Richard Rodgers IND (54)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 14th, 2005
- Public Since
- November 30th, 2004
- No. of Shareholders
- 67
- No. of Employees
- 18
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 45,483,823
- Address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, 27709
- Web
- https://opusgtx.com/
- Phone
- +1 2486819815
- Auditors
- Ernst & Young LLP
Upcoming Events for IRD
Opus Genetics Inc Annual Shareholders Meeting
Q2 2025 Opus Genetics Inc Earnings Release
Similar to IRD
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Opus Genetics share price?
As of Today at 22:27 UTC, shares in Opus Genetics are trading at $0.76. This share price information is delayed by 15 minutes.
How has the Opus Genetics share price performed this year?
Shares in Opus Genetics last closed at $0.76 and the price had moved by -56.33% over the past 365 days. In terms of relative price strength the Opus Genetics share price has underperformed the S&P500 Index by -58.94% over the past year.
What are the analyst and broker recommendations for Opus Genetics?
The overall consensus recommendation for Opus Genetics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Opus Genetics dividend yield?
Opus Genetics does not currently pay a dividend.
Does Opus Genetics pay a dividend?
Opus Genetics does not currently pay a dividend.
When does Opus Genetics next pay dividends?
Opus Genetics does not currently pay a dividend.
How do I buy Opus Genetics shares?
To buy shares in Opus Genetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Opus Genetics?
As of the previous close price of $0.76, shares in Opus Genetics had a market capitalisation of $34.56m.
Where are Opus Genetics shares listed?
Here are the trading details for Opus Genetics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IRD
What kind of share is Opus Genetics?
Based on an overall assessment of its quality, value and momentum Opus Genetics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Opus Genetics share price forecast for 2025?
The analyst consensus target price for shares in Opus Genetics is $9.25. That is 1117.27% above the last closing price of $0.76.
Analysts covering Opus Genetics currently have a consensus Earnings Per Share (EPS) forecast of -$0.90 for the next financial year.
Find out moreWhat is the trend in the Opus Genetics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Opus Genetics. Over the past six months, its share price has underperformed the S&P500 Index by -36.21%.
As of the last closing price of $0.76, shares in Opus Genetics were trading -38.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Opus Genetics PE Ratio?
The Opus Genetics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Opus Genetics?
Opus Genetics' management team is headed by:
- Cam Gallagher - NEC
- Mina Sooch - PRE
- Amy Rabourn - CAO
- Bernhard Hoffmann - VOP
- Sean Ainsworth - LED
- Jay Pepose - DRC
- Susan Benton - IND
- James Manuso - IND
- Richard Rodgers - IND